Ubs Group Ag Bio Affinity Technologies, Inc. Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Bio Affinity Technologies, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 24 shares of BIAF stock, worth $58. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Holding current value

$58

% of portfolio

0.0%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$0.2 - $1.09 $4 - $26	24 New	24 $0
Q2 2024 Aug 13, 2024	BUY	$1.76 - $3.0 $16,880 - $28,773	9,591 New	9,591 $20,000
Q3 2023 Nov 09, 2023	SELL	$0.99 - $1.9 $29 - $57	-30 Reduced 31.58%	65 $0
Q2 2023 Aug 11, 2023	SELL	$1.56 - $2.05 $3,609 - $4,743	-2,314 Reduced 96.06%	95 $0
Q1 2023 May 12, 2023	SELL	$1.52 - $3.06 $6,341 - $12,766	-4,172 Reduced 63.39%	2,409 $4,000
Q4 2022 Feb 08, 2023	BUY	$1.6 - $3.14 $2,652 - $5,206	1,658 Added 33.68%	6,581 $10,000
Q3 2022 Nov 10, 2022	BUY	$2.11 - $8.3 $10,387 - $40,860	4,923 New	4,923 $14,000

Others Institutions Holding BIAF

# of Institutions

Shares Held

416K

Call Options Held

Put Options Held

View Full List

About bioAffinity Technologies, Inc.

Ticker BIAF
Exchange
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 2,727,580
Market Cap $6.68M
Description
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is b...

More about BIAF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account